CoChat
Cited by 45

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Cannabinoid CB2 Receptors Modulate Microglia Function and Amyloid Dynamics in a Mouse Model of Alzheimer’s Disease

Ruiz de Martín Esteban, Samuel, Benito-Cuesta, Irene, Terradillos, Itziar, Martínez-Relimpio, Ana M., Arnanz, M. Andrea, Ruiz-Pérez, Gonzalo, Korn, Claudia, Raposo, Catarina, Sarott, Roman C., Westphal, Matthias V., Elezgarai, Izaskun, Carreira, Erick M., Hillard, Cecilia J., Grether, Uwe, Grandes, Pedro, Grande, M. Teresa, Romero, Julián · 2022 · Frontiers in Pharmacology

Abstract

The distribution and roles of the cannabinoid CB 2 receptor in the CNS are still a matter of debate. Recent data suggest that, in addition to its presence in microglial cells, the CB 2 receptor may be also expressed at low levels, yet biologically relevant, in other cell types such as neurons. It is accepted that the expression of CB 2 receptors in the CNS is low under physiological conditions and is significantly elevated in chronic neuroinflammatory states associated with neurodegenerative diseases such as Alzheimer’s disease. By using a novel mouse model (CB 2EGFP/f/f), we studied the distribution of cannabinoid CB 2 receptors in the 5xFAD mouse model of Alzheimer’s disease (by generating 5xFAD/CB 2EGFP/f/f mice) and explored the roles of CB 2 receptors in microglial function. We used a novel selective and brain penetrant CB 2 receptor agonist (RO6866945) as well as mice lacking the CB 2 receptor (5xFAD/CB 2−/−) for these studies. We found that CB 2 receptors are expressed in dystrophic neurite-associated microglia and that their modulation modifies the number and activity of microglial cells as well as the metabolism of the insoluble form of the amyloid peptide. These results support microglial CB 2 receptors as potential targets for the development of amyloid-modulating therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2022.841766

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 25

  1. Aso, 2016, Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine, J. Alzheimers Dis., 51, 489, 10.3233/JAD-150913 · DOI
  2. Benito, The Endocannabinoid System and Alzheimer's Disease, Mol. Neurobiol., 36, 75, 10.1007/s12035-007-8006-8 · DOI
  3. Benito, 2003, Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains, J. Neurosci., 23, 11136, 10.1523/jneurosci.23-35-11136.2003 · DOI · Paper page
  4. Cabañero, 2020, Protective Role of Neuronal and Lymphoid Cannabinoid CB2 Receptors in Neuropathic Pain, Elife, 9, e55582, 10.7554/eLife.55582 · DOI
  5. Espejo-Porras, 2019, Targeting Glial Cannabinoid CB2 Receptors to Delay the Progression of the Pathological Phenotype in TDP-43 (A315T) Transgenic Mice, a Model of Amyotrophic Lateral Sclerosis, Br. J. Pharmacol., 176, 1585, 10.1111/bph.14216 · DOI
  6. Galán-Ganga, 2021, Cannabinoid Receptor CB2 Ablation Protects against TAU Induced Neurodegeneration, Acta Neuropathol. Commun., 9, 90, 10.1186/s40478-021-01196-5 · DOI
  7. He, 2021, β-Caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms, Front. Pharmacol., 12, 722476, 10.3389/fphar.2021.722476 · DOI
  8. Komorowska-Müller, 2020, CB2 Receptor in Microglia: The Guardian of Self-Control, Int. J. Mol. Sci., 22, 19, 10.3390/ijms22010019 · DOI · Paper page
  9. Koppel, 2014, CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease, Mol. Med., 20, 29, 10.2119/molmed.2013.00140.revised · DOI
  10. López, 2018, Cannabinoid CB2 Receptors in the Mouse Brain: Relevance for Alzheimer's Disease, J. Neuroinflammation, 15, 158, 10.1186/s12974-018-1174-9 · DOI · Paper page
  11. Maresz, 2005, Modulation of the Cannabinoid CB2 Receptor in Microglial Cells in Response to Inflammatory Stimuli, J. Neurochem., 95, 437, 10.1111/j.1471-4159.2005.03380.x · DOI · Paper page
  12. Mecha, 2016, Microglia Activation States and Cannabinoid System: Therapeutic Implications, Pharmacol. Ther., 166, 40, 10.1016/j.pharmthera.2016.06.011 · DOI · Paper page
  13. Nimmerjahn, 2005, Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma In Vivo, Science, 308, 1314, 10.1126/science.1110647 · DOI · Paper page
  14. Onaivi, 2008, Functional Expression of Brain Neuronal CB2 Cannabinoid Receptors are Involved in the Effects of Drugs of Abuse and in Depression, Ann. N. Y. Acad. Sci., 1139, 434, 10.1196/annals.1432.036 · DOI · Paper page
  15. Ouali Alami, 2018, NF-κB Activation in Astrocytes Drives a Stage-Specific Beneficial Neuroimmunological Response in ALS, EMBO J., 37, e98697, 10.15252/embj.201798697 · DOI
  16. Pertwee, 2010, International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: beyond CB₁ and CB₂, Pharmacol. Rev., 62, 588, 10.1124/pr.110.003004 · DOI · Paper page
  17. Puente, 2019, High-Resolution Immunoelectron Microscopy Techniques for Revealing Distinct Subcellular Type 1 Cannabinoid Receptor Domains in Brain, Bio Protoc., 9, e3145, 10.21769/BioProtoc.3145 · DOI
  18. Querfurth, 2010, Alzheimer's Disease, N. Engl. J. Med., 362, 329, 10.1056/NEJMra0909142 · DOI · Paper page
  19. Reusch, 2022, Cannabinoid Receptor 2 Is Necessary to Induce Toll-like Receptor-Mediated Microglial Activation, Glia, 70, 71, 10.1002/glia.24089 · DOI
  20. Rodríguez-Cueto, 2021, Inactivation of the CB 2 Receptor Accelerated the Neuropathological Deterioration in TDP‐43 Transgenic Mice, a Model of Amyotrophic Lateral Sclerosis, Brain Pathol., 31, e12972, 10.1111/bpa.12972 · DOI
  21. Sarott, 2020, Development of High-Specificity Fluorescent Probes to Enable Cannabinoid Type 2 Receptor Studies in Living Cells, J. Am. Chem. Soc., 142, 16953, 10.1021/jacs.0c05587 · DOI
  22. Savonenko, 2015, Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation, PLoS One, 10, e0129618, 10.1371/journal.pone.0129618 · DOI
  23. Schmöle, 2015, Cannabinoid Receptor 2 Deficiency Results in Reduced Neuroinflammation in an Alzheimer's Disease Mouse Model, Neurobiol. Aging, 36, 710, 10.1016/j.neurobiolaging.2014.09.019 · DOI
  24. Schmöle, 2018, Cannabinoid Receptor 2-Deficiency Ameliorates Disease Symptoms in a Mouse Model with Alzheimer's Disease-Like Pathology, J. Alzheimers. Dis., 64, 379, 10.3233/JAD-180230 · DOI
  25. Wu, 2017, Activation of CB2 Receptor System Restores Cognitive Capacity and Hippocampal Sox2 Expression in a Transgenic Mouse Model of Alzheimer's Disease, Eur. J. Pharmacol., 811, 12, 10.1016/j.ejphar.2017.05.044 · DOI

Cited by

See all 45

Metadata

Authors
Ruiz de Martín Esteban, S., Benito-Cuesta, I., Terradillos, I., Martínez-Relimpio, A. M., Arnanz, M. A., Ruiz-Pérez, G., Korn, C., Raposo, C., Sarott, R. C., Westphal, M. V., Elezgarai, I., Carreira, E. M., Hillard, C. J., Grether, U., Grandes, P., Grande, M. T., & Romero, J.
Venue
Frontiers in Pharmacology
Published
2022-04-27
Volume
13
ISSN
1663-9812
Cited by
45
References
13

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cannabinoid CB2 Receptors Modulate Microglia Function and Amyloid Dynamics in a Mouse Model of Alzheimer’s Disease. https://app.cochat.ai/papers/10.3389/fphar.2022.841766
The paper
Ruiz de Martín Esteban, S., Benito-Cuesta, I., Terradillos, I., Martínez-Relimpio, A. M., Arnanz, M. A., Ruiz-Pérez, G., Korn, C., Raposo, C., Sarott, R. C., Westphal, M. V., Elezgarai, I., Carreira, E. M., Hillard, C. J., Grether, U., Grandes, P., Grande, M. T., & Romero, J. (2022). Cannabinoid CB2 Receptors Modulate Microglia Function and Amyloid Dynamics in a Mouse Model of Alzheimer’s Disease. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.841766

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.